2021-2030 Analysis and Review Amifostine Hydrate Market
Amifostine Hydrate Market By Indication (Cumulative Renal Toxicity and Xerostomia), By End User (Hospitals & Clinics, Rehabilitation Centers and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The Amifostine Hydrate market was valued at USD50.4 Mn by 2019. As per the latest research citings presented by the World Health Organization (WHO), cancer is the second leading cause of death worldwide occurring in about 1 in 6th individuals throughout the globe. Amifostine Hydrate is critical in reducing the nephrotoxicity and xerostomia associated with chemotherapy and radiation therapy. It is the most popular adjuvant therapy prescribed by oncologists owing to its cytoprotective activity.
Amifostine hydrate is available as a single dose vial of 500mg intended for intravenous administration, it needs to be reconstituted with 9.7 ml of sodium chloride (0.9%) injection. The reconstituted mixture is stable for 5 hours at room temperature and 24 hours if kept in a refrigerator. It needs to be given 30 minutes prior to chemotherapy and the blood pressure needs to be constantly monitored every 5 minutes during the infusion. The recommended dose to reduce cumulative renal toxicity is 910 mg/m2 once every day as a 15 minutes infusion, it needs to be given 30 minutes prior to chemotherapy and the blood pressure needs to be constantly monitored every 5 minutes during the infusion. The recommended dose for xerostomia is 200 mg/m2once every day as a 3-minute infusion usually 15 minutes before radiation therapy.
The major segments related to the Amifostine Hydrate market are:
By Indication (2017–2027; US$ Mn)
Cumulative Renal Toxicity
Xerostomia
By End User (2017–2027; US$ Mn)
Hospitals & Clinics
Rehabilitation Centers
Others
Geography Segment(2017–2027; US$ Mn)
North America
United States
Canada
Europe
United Kingdom
Germany
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
Significant customers?
Segment Analysis
As per the research citings presented by the European Society for Medical Oncology (ESMO) the head and neck cancer is the 6th most malignant type of cancer throughout the world. The majority of the patients opt for radiation therapy which eventually results in xerostomia. Cumulative renal toxicity is the fastest-growing segment for the Amifostine hydrate market. According to the research citings brought forward by the World Cancer Research Fund in 2018, approximately 300,000 new cases of ovarian cancer in women were reported worldwide. Repeated chemo cycles of cisplatin is administered by intravenous injection in patients suffering from ovarian cancer. Nephrotoxicity occurs as an adverse effect associated with cisplatin chemotherapy. Amifostine hydrate is used as an adjuvant therapy due to its cytoprotective activity on the healthy renal cells.
Hospitals and clinics are currently leading the end-user segment for the Amifostine hydrate market. The significant rise in inpatient admission due to a concomitant increase in the number of new cancer diagnosed patients. Availability of Amifostine hydrate injection at a subsidized price in government-funded cancer hospitals & clinics worldwide. Rehabilitation centers have gained tremendous traction in the last decade on account of its ability to prevent distress and mental strain in patients receiving chemotherapy and radiation therapy which is associated with severe side effects. Rehabilitation centers are critical in restoring physical and mental health in patients undergoing cancer treatment.
North America is spearheading the geography segment for the Amifostine Hydrate market. As per the latest statistics provided by the Ovarian Cancer Research Alliance in 2019, the estimated number of new cases of ovarian cancer is 22,530 in the United States. The rising prevalence of cumulative renal toxicity associated with cisplatin therapy in patients suffering from ovarian cancer primarily determines the Amifostine Hydrate market growth in North America. Affordable reimbursement scenario associated with the generic injection of Amifostine Hydrate further accentuates its market growth in the region. According to the latest research citings brought forward by the European Society for Medical Oncology (ESMO) the annual incidence rate associated with head and neck cancer in the European region is 43 per 100,000 people. Rising prevalence of xerostomia in patients receiving radiation therapy for head and neck cancer determines the Amifostine market growth in Europe. It is anticipated that the Asia Pacific is set to record rampant market growth in the near future on account of the significant rise in the medical tourism industry and the presence of a huge generic drug market.
$4,600 | |
$6,600 | |
$9,500 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |